News · 26 weeks61+14%
2025-11-022026-04-26
Mix2890d
- Insider13(46%)
- SEC Filings7(25%)
- Other5(18%)
- Earnings3(11%)
Latest news
25 items- PRSight Sciences to Present at Two Upcoming Investor ConferencesMENLO PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at two upcoming conferences. BofA Securities 2026 Health Care Conference in Las Vegas, NV on Wednesday, May 13, 2026, at 3:15 pm PT / 6:15 pm ET. Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 9:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the presentation and fireside chat on the "Investors" section of the
- SECSight Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sight Sciences, Inc. (0001531177) (Filer)
- PRSight Sciences Announces the Release of its Sustainability ReportMENLO PARK, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company's sustainability activities, performance and results from the last three years. "We are proud to issue our third Sustainability Report, reflecting our continued progress in transparency, operational discipline, and environmental impact reduction, while reinforcing our commitment to creating long term value for all stakeholders," stated Paul Badawi, co-founder
- SECSEC Form DEFA14A filed by Sight Sciences Inc.DEFA14A - Sight Sciences, Inc. (0001531177) (Filer)
- SECSEC Form DEF 14A filed by Sight Sciences Inc.DEF 14A - Sight Sciences, Inc. (0001531177) (Filer)
- PRSight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2026, after the market close on Wednesday, May 6, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at ww
- INSIDERSEC Form 4 filed by Rodberg James4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERSEC Form 4 filed by Hayden Jeremy B.4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERSEC Form 4 filed by Bauerlein Alison4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERSEC Form 4 filed by Badawi David4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERSEC Form 4 filed by Taylor Brenton4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERSEC Form 4 filed by Badawi Paul4 - Sight Sciences, Inc. (0001531177) (Issuer)
- PRSight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13thMENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 25th Annual Needham Healthcare Conference being held virtually. Sight Sciences' management is scheduled to present on Monday, April 13, 2026, at 11:15 am PT / 2:15 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the Company's website at https://investors.sightsciences.com/. About Sight Scienc
- SECSight Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sight Sciences, Inc. (0001531177) (Filer)
- PRSight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® MicrostentMENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that the U.S. District Court for the District of Delaware (the Court) issued an order on post-trial motions in Sight Sciences' patent infringement case against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, Alcon) originally filed on September 16, 2021, that preserved the jury's verdict of willful infringement. Sight Sciences asserted that Alcon's sal
- SECSEC Form 10-K filed by Sight Sciences Inc.10-K - Sight Sciences, Inc. (0001531177) (Filer)
- SECSight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sight Sciences, Inc. (0001531177) (Filer)
- PRSight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial GuidanceMENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026. Recent Financial Highlights Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2
- INSIDERChief Technology Officer Badawi David exercised 21,270 shares at a strike of $0.23, increasing direct ownership by 1% to 1,998,458 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- PRSight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast
- INSIDERChief Technology Officer Badawi David was granted 64,915 shares, increasing direct ownership by 3% to 1,977,188 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERChief Operating Officer Bauerlein Alison was granted 127,512 shares, increasing direct ownership by 21% to 727,495 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERChief Legal Officer Hayden Jeremy B. was granted 115,920 shares, increasing direct ownership by 43% to 383,531 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERPresident and CEO Badawi Paul was granted 154,560 shares, increasing direct ownership by 3% to 6,180,400 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERChief Financial Officer Rodberg James was granted 86,940 shares, increasing direct ownership by 57% to 238,170 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
SGHT FAQ
7 questionsWhat does Sight Sciences Inc. do?
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals...Where does SGHT stock trade?
Sight Sciences Inc. (SGHT) is listed on NASDAQ.What sector and industry is SGHT in?
Sight Sciences Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Sight Sciences Inc. go public?
Sight Sciences Inc. (SGHT) completed its IPO in 2021.What are analysts saying about SGHT?
Sight Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $900.00 price target on 2026-01-05. Recent price targets range from $450.00 to $1000.00.What companies are similar to SGHT?
Notable peers in the same industry include SYK (Stryker Corporation), BSX (Boston Scientific Corporation), MMM (3M Company), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare SGHT side-by-side with any of them on Quantisnow.How can I track SGHT on Quantisnow?
Quantisnow aggregates Sight Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SGHT to receive live email and push alerts on every new disclosure.